Total Return chart SynAct Pharma AB

Stocks

Market Closed - Nasdaq Stockholm 12:00:00 2026-10-21 EDT			5-day change	1st Jan Change
17.44 ^SEK	+1.63%		+2.59%	-22.83%

09-16	Synact Pharma's resomelagon highlighted by WHO for dengue fever	FW
09-16	SynAct Pharma Identifies Resomelagon As One Of Six Dengue Drug Candidates With Evidence Supporting Further Clinical Development	CI

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.